Bioporto and physician develop new blood test to predict organ failure
In collaboration with physician and professor Pär Ingemar Johansson, Danish Bioporto is developing a new diagnostic test to trace damages of the smallest blood vessels in the body. The project can potentially bring about a new portfolio product to accompany Bioporto's kidney injury biomarker.
While Bioporto anxiously awaits FDA's approval of its main asset, the NGAL test, the company is already in the first stages of development of a brand new product.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
